Literature DB >> 33931501

Impairment of the neurotrophic signaling hub B-Raf contributes to motoneuron degeneration in spinal muscular atrophy.

Niko Hensel1,2, Federica Cieri3,4, Pamela Santonicola3, Ines Tapken5,2, Tobias Schüning5,2, Michela Taiana6, Elisa Pagliari6, Antonia Joseph5, Silke Fischer5, Natascha Heidrich5, Hella Brinkmann5, Sabrina Kubinski5,2, Anke K Bergmann7, Manuela F Richter8, Klaus Jung2,9, Stefania Corti6,10, Elia Di Schiavi3, Peter Claus5,2.   

Abstract

Spinal muscular atrophy (SMA) is a motoneuron disease caused by deletions of the Survival of Motoneuron 1 gene (SMN1) and low SMN protein levels. SMN restoration is the concept behind a number of recently approved drugs which result in impressive yet limited effects. Since SMN has already been enhanced in treated patients, complementary SMN-independent approaches are needed. Previously, a number of altered signaling pathways which regulate motoneuron degeneration have been identified as candidate targets. However, signaling pathways form networks, and their connectivity is still unknown in SMA. Here, we used presymptomatic SMA mice to elucidate the network of altered signaling in SMA. The SMA network is structured in two clusters with AKT and 14-3-3 ζ/δ in their centers. Both clusters are connected by B-Raf as a major signaling hub. The direct interaction of B-Raf with 14-3-3 ζ/δ is important for an efficient neurotrophic activation of the MEK/ERK pathway and crucial for motoneuron survival. Further analyses in SMA mice revealed that both proteins were down-regulated in motoneurons and the spinal cord with B-Raf being reduced at presymptomatic stages. Primary fibroblasts and iPSC-derived motoneurons from SMA patients both showed the same pattern of down-regulation. This mechanism is conserved across species since a Caenorhabditis elegans SMA model showed less expression of the B-Raf homolog lin-45 Accordingly, motoneuron survival was rescued by a cell autonomous lin-45 expression in a C. elegans SMA model resulting in improved motor functions. This rescue was effective even after the onset of motoneuron degeneration and mediated by the MEK/ERK pathway.

Entities:  

Keywords:  14-3-3; Raf; SMA; neurotrophic signaling; spinal muscular atrophy

Mesh:

Substances:

Year:  2021        PMID: 33931501      PMCID: PMC8106332          DOI: 10.1073/pnas.2007785118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  86 in total

1.  Positive and negative regulation of Raf kinase activity and function by phosphorylation.

Authors:  H Chong; J Lee; K L Guan
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

2.  Phosphorylation of more than one site is required for tight interaction of human tau protein with 14-3-3zeta.

Authors:  Nikolai N Sluchanko; Alim S Seit-Nebi; Nikolai B Gusev
Journal:  FEBS Lett       Date:  2009-08-03       Impact factor: 4.124

3.  Craf-1 protein kinase is essential for mouse development.

Authors:  L Wojnowski; L F Stancato; A M Zimmer; H Hahn; T W Beck; A C Larner; U R Rapp; A Zimmer
Journal:  Mech Dev       Date:  1998-08       Impact factor: 1.882

4.  Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.

Authors:  Eugenio Mercuri; Basil T Darras; Claudia A Chiriboga; John W Day; Craig Campbell; Anne M Connolly; Susan T Iannaccone; Janbernd Kirschner; Nancy L Kuntz; Kayoko Saito; Perry B Shieh; Már Tulinius; Elena S Mazzone; Jacqueline Montes; Kathie M Bishop; Qingqing Yang; Richard Foster; Sarah Gheuens; C Frank Bennett; Wildon Farwell; Eugene Schneider; Darryl C De Vivo; Richard S Finkel
Journal:  N Engl J Med       Date:  2018-02-15       Impact factor: 91.245

5.  Automated screening of C. elegans neurodegeneration mutants enabled by microfluidics and image analysis algorithms.

Authors:  Ivan de Carlos Cáceres; Daniel A Porto; Ivan Gallotta; Pamela Santonicola; Josue Rodríguez-Cordero; Elia Di Schiavi; Hang Lu
Journal:  Integr Biol (Camb)       Date:  2018-09-17       Impact factor: 2.192

6.  Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.

Authors:  L Brichta; Y Hofmann; E Hahnen; F A Siebzehnrubl; H Raschke; I Blumcke; I Y Eyupoglu; B Wirth
Journal:  Hum Mol Genet       Date:  2003-07-29       Impact factor: 6.150

7.  Regulation of RAF activity by 14-3-3 proteins: RAF kinases associate functionally with both homo- and heterodimeric forms of 14-3-3 proteins.

Authors:  Andreas Fischer; Angela Baljuls; Joerg Reinders; Elena Nekhoroshkova; Claudia Sibilski; Renate Metz; Stefan Albert; Krishnaraj Rajalingam; Mirko Hekman; Ulf R Rapp
Journal:  J Biol Chem       Date:  2008-12-02       Impact factor: 5.157

8.  The genetics of Caenorhabditis elegans.

Authors:  S Brenner
Journal:  Genetics       Date:  1974-05       Impact factor: 4.562

Review 9.  Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer.

Authors:  Marta Falcicchio; Jake A Ward; Salvador Macip; Richard G Doveston
Journal:  Cell Death Discov       Date:  2020-11-16

10.  Key role of SMN/SYNCRIP and RNA-Motif 7 in spinal muscular atrophy: RNA-Seq and motif analysis of human motor neurons.

Authors:  Federica Rizzo; Monica Nizzardo; Shikha Vashisht; Erika Molteni; Valentina Melzi; Michela Taiana; Sabrina Salani; Pamela Santonicola; Elia Di Schiavi; Monica Bucchia; Andreina Bordoni; Irene Faravelli; Nereo Bresolin; Giacomo Pietro Comi; Uberto Pozzoli; Stefania Corti
Journal:  Brain       Date:  2019-02-01       Impact factor: 13.501

View more
  2 in total

Review 1.  Protein Network Analysis Reveals a Functional Connectivity of Dysregulated Processes in ALS and SMA.

Authors:  Sabrina Kubinski; Peter Claus
Journal:  Neurosci Insights       Date:  2022-03-28

2.  Neuromuscular denervation and deafferentation but not motor neuron death are disease features in the Smn2B/- mouse model of SMA.

Authors:  Maria J Carlini; Marina K Triplett; Livio Pellizzoni
Journal:  PLoS One       Date:  2022-08-01       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.